AI Health Technology Limited
智慧健康科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1715)

PROFIT WARNING

This announcement is made by AI Health Technology Limited (the "**Company**" and its subsidiaries, collectively the "**Group**") pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Directors**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and the potential investors that, based on the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 (the "**Interim Period**") and information currently available to the Company, the Group expects to record a net loss after tax of approximately RMB19.5 million for the Interim Period, as compared with a net loss after tax of approximately RMB11.5 million for the corresponding period in 2025.

During the Interim Period, such increase in net loss was mainly due to the combined results of (i) an increase in selling and distribution expenses by approximately RMB1.6 million, primarily attributable to intensified promotional and market development efforts in the health-related business; (ii) an increase in administrative expenses by approximately RMB1.3 million, reflecting personnel and general operational costs incurred to support the development of the health-related business; and (iii) an increase in the research and development expense by approximately RMB3.4 million, resulting from the Group's development of a new comprehensive marketing solution system.

The Company is still in the process of finalizing the unaudited consolidated financial results of the Group for the Interim Period. The information contained in this announcement is only based on the information currently available to the Company and the preliminary review by the Board on the unaudited consolidated management accounts of the Group for the Interim Period, which have not been confirmed, reviewed or audited by the independent auditors and/or the audit committee of the Company. The actual financial results of the Group for the Interim Period may differ from what is disclosed in this announcement. Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for the Interim Period, which is expected to be published in August 2026 in accordance with the requirements of the Listing Rules.

Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By Order of the Board
AI Health Technology Limited
Zhao Jie
Executive Director

Hong Kong, 12 August 2026

As at the date of this announcement, the executive Directors of the Company are Mr. Zhao Jie, Madam Maeck Can Yue and Ms. Wang Jian, and the independent non-executive Directors of the Company are Mr. Lin Dongming, Mr. Shen Shujing and Ms. Zhang Yuanjie.